Niacin and analogs for phosphate control in dialysis-perspective from a developing country

International Urology and Nephrology

Volumn 41, Issue 4, 2009, Pages 913-918

  Sampathkumar, Krishnaswamy ^a  

^a Meenakshi Mission Hospital   (India)

Author keywords

Calcium; Dialysis; End stage renal disease; HDL; Na Pi cotransporter; Niacin; Niacinamide; Phosphate binders

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; HIGH DENSITY LIPOPROTEIN; LANTHANUM CARBONATE; NICERITROL; NICOTINAMIDE; NICOTINIC ACID; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; SODIUM PHOSPHATE COTRANSPORTER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DIARRHEA; DRUG COST; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG WITHDRAWAL; DYSLIPIDEMIA; GOUT; HEMODIALYSIS; HOT FLUSH; HUMAN; HYPERPHOSPHATEMIA; HYPOTENSION; INHIBITION KINETICS; INTESTINE ABSORPTION; KIDNEY FAILURE; LIVER FAILURE; MEDICAL RESEARCH; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PEPTIC ULCER; PERITONEAL DIALYSIS; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RISK MANAGEMENT; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; COST SAVINGS; DEVELOPING COUNTRIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPHOSPHATEMIA; INTESTINAL ABSORPTION; KIDNEY FAILURE, CHRONIC; MALE; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 77949567831     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9497-6     Document Type: Review

References (34)

1. Miller DF (1978) Pellagra deaths in the United States. Am J Clin Nutr 31(4):558-559
2. Altschul R, Hoffer A, Stephen JD (1955) Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54:558-559. doi:10.1016/0003-9861(55) 90070-9
3. Foley RN, Murray AM, Li S (2005) Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the united states medicare population, 1998 to 1999. J Am Soc Nephrol 16:489-495. doi:10.1681/ASN.2004030203 (Pubitemid 41725146)
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218. doi:10.1097/01.ASN.0000133041. 27682.A2
5. Young EW, Akiba T, Albert J (2004) Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 44(Supl. 3):S34-S38
6. Kestenbaum B, Sampson JN, Rudser KD (2004) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520-528. doi:10.1681/ASN.2004070602
7. Sankarasubbaiyan S, Abraham G, Soundararajan P et al (2005) Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India. Hemodial Int Jan; 9(1):63-67
8. Tomasellow S, Dhupar S, Sherman RA (2004) Phosphate binders, K/DOQI guidelines and compliance: the unfortunate reality. Dial Transplant 33(5):236-240
9. Tzanakis IP, Papadaki AN, Wei M et al (2008) Magnesium carbonate for phosphate control for patients on hemodialysis randomized controlled trial. Int Urol Nephrol 40:193-201. doi:10.1007/s11255-007-9300-0
10. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252. doi:10.1046/j.1523-1755.2002.00434.x (Pubitemid 34754068)
11. Berns JS (2008) Niacin and related compounds for treating hyperphosphatemia in dialysis patients. Semin Dial 21(3):203-205. doi:10.1111/j.1525-139X.2008.00426.x
12. Shimoda K, Akiba T, Matsushima T, Rai T et al (1998) Niceriotol decreases serum phosphate levels in chronic hemodialysis patients. Nippon Jinzo Gakkai Shi 40:1-7
13. Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T (1999) Effects of niceritol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 14:610-614. doi:10.1093/ndt/14.3.610
14. Hilfiker H, Hattenhauer O, Murer H et al (1998) Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci USA 95:14564-14569. doi:10.1073/ pnas.95.24.14564
15. Tenenhouse HS (2005) Regulation of phosphorus homeostasis by the type IIa Na/phosphate cotransporter. Annu Rev Nutr 25:197-214. doi:10.1146/annurev.nutr. 25.05030 4.092642
16. Eto N, Miyata Y, Ohno H, Yamashita T (2005) Nicotinamide prevents the development of hyperphosphatemia by suppressing the intestinal sodium dependent phosphate transporter in rats with adenine induced renal failure. Nephrol Dial Transplant 20:1378-1384. doi:10.1093/ndt/ gfh781
17. Takahashi Y, Tanaka A et al (2004) Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099-1104
18. Sampathkumar K, Selvam M, Sooraj Y, Gowthaman S, Ajeshkumar R (2006) Extended release nicotinic acid is a novel agent for Phosphate control in dialysis. Int Urol Nephrol 38:171-174. doi:10. 1007/s11255-006-0001-x
19. Sampathkumar K, Sooraj Y, Mahaldar AR (2007) Comparative efficacy of low dose nicotinic acid and Lanthanum in lowering the Phosphorus levels in hemodialysis patients. S-PO-0327-Paper presented at WCN 2007, Rio de Janeiro, Brazil
20. Müller D, Mehling H et al (2007) Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2:1249-1254. doi:10.2215/CJN.01470307
21. Cheng SC, Young DO (2008) A Randomized, doubleblind, placebo-controlled trial of Niacinamide for reduction of Phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3:1131-1138. doi:10. 2215/CJN.04211007
22. Musso CG, Reynaldi MJ, Aparicio C et al. (2007) Hyperphosphatemia and nicotinic acid in peritoneal dialysis patients. Int Urol Nephrol 229-230
23. Restrepo Valencia A, Cruz J (2008) Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia C. Nefrologia 28(1):61-66
24. Karpe F, Frayn KN (2004) The nicotinic acid receptor-a new mechanism for an old drug. Lancet 363: 1892-1894. doi:10. 1016/S0140-6736(04)16359-9
25. Hunsicker LG, Adler S, Caggiula A et al (1997) Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51(6):1908-1919. doi:10. 1038/ki. 1997.260
26. Manttari M, Tiula E, Alikoski T, Manninen V (1995) Effects of hypertension and dyslipidaemia on the decline in renal function. Hypertension 26(4):670-675
27. Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar RB, Kothari K (2004) Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol 97(2):257-261. doi:10. 1016/j.ijcard. 2003.11.003
28. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V (2003) Metabolic syndrome in urban Asian Indian adults-a population study using modified ATP III criteria. Diabetes Res Clin Pract Jun;60(3):199-204
29. Reddy KS, Shah B, Varghese C, Ramadoss A (2005) Responding to the threat of chronic diseases in India. Lancet 366:1746-1751
30. Abo-zenah H, Sabry A, Farouk A et al (2007) Impact of hemodialysis associated variables in lipid profiles in Egyptian hemodialysis population. Int Urol Nephrol 39:609-618. doi:10. 1007/s11255-006- 9162-x
31. Kaysen GA (2006) Dyslipidemia in chronic kidney disease: causes and consequences. Kidney Int 70:S55-S58
32. Sheherd J, Packard CJ, Patsch JR et al (1979) Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 63:858-867. doi: 10. 1172/JCI109385
33. Rottembourg JB, Launay-Vacher V, Massard J (2005) Thrombocytopenia induced by nicotinamide in hemodial-ysis patients. Kidney Int 68:2911-2912. doi:10. 1111/ j. 1523-1755. 2005. 00583-8.x
34. O'Brien T, Silverberg J, Nguyen T (1992) Nicotinic acidinduced toxicity associated with cytopenia and decreased level of thyroxin-binding globulin. Mayo Clin Proc 67:465-468